SAGA Diagnostics has entered into an assay development agreement with AstraZeneca.
SAGA Diagnostics will in the course of this agreement develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies.
“We have chosen to partner with SAGA because of the ultrasensitive performance of the SAGAsafe technology and possibility to custom tailor highly complex dPCR assays to meet our desired analytical standards. We are excited about exploring this new area together with SAGA,” says James Hadfield, Director Epigenomics, Oncology Translational Medicine, Oncology R&D, AstraZeneca
SAGAsafe is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods and can be used to quantify sequence variants in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance.
“We are honored that Dr. Hadfield and his team have selected SAGA and the SAGAsafe platform to develop ultrasensitive dPCR methylation assays for AstraZeneca’s clinical research study, and are pleased to be working together again,” says Lao Saal, co-founder and COO of SAGA Diagnostics.
Photo of Lao Saal: SAGA Diagnostics